|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of age and gut dysbiosis on the development of CNS autoimmunity in humanized transgenic mice expressing the MS-associated MHC class II (MHC-II) gene, HLA-DR2a, and T-cell receptor (TCR) genes specific for MBP87-99/DR2a that were derived from an MS patient.
|
29078267 |
2017 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we genotyped 1,784 patients and 1,660 healthy controls from Scandinavia for the HLA-A, HLA-B, HLA-C and HLA-DRB1 genes and investigated their effects on MS risk by logistic regression.
|
22586495 |
2012 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides myelin proteins, lipid components of CNS are supposed to play a role as antigens for T cells in MS. CD1 is a family of MHC-like glycoproteins specialized in capturing and presenting a variety of microbial and self lipids and glycolipids to antigen-specific T cells.
|
21496400 |
2011 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antigen-presenting cell-associated four-domain MHC class II (MHC-II) molecules play a central role in activating autoreactive CD4(+) T cells involved in multiple sclerosis (MS) and type 1 diabetes (T1D).
|
21469129 |
2011 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of HLA A*02 with multiple sclerosis (MS) was recently confirmed by the authors, and it was observed that the combined presence of HLA Cw*05 significantly enhanced (threefold) the protective effect of HLA A*02.
|
21441263 |
2011 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of multiple sclerosis (MS) is influenced by HLA-DRB1, while protective effects have been proposed for HLA-A*02 and HLA-C*05.
|
20678810 |
2010 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Examination of an HLA-C 5' flanking region SNP rs9264942, known to correlate with HLA-C expression, showed a protective association in girls (OR = 0.4, 95% CI = 0.2-0.7, Mantel-Haenszel P = 0.0003) similar to the protective HLA-Cw*05 association in MS.
|
21067287 |
2010 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies reported an association with multiple sclerosis (MS) of distinct HLA-class I markers, namely HLA-A*02, HLA-Cw*05 and MOG-142L.
|
19907433 |
2010 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition to the main multiple sclerosis (MS) major histocompatibility complex (MHC) risk allele (HLA DRB1*1501), investigations of the MHC have implicated several class I MHC loci (HLA A, HLA B, and HLA C) as potential independent MS susceptibility loci.
|
20713950 |
2010 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis.
|
16459714 |
2006 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although there is evidence that the development of MS is determined by both environmental influences and genes, these factors are largely undefined, except for major histocompatibility (MHC) genes.
|
10610182 |
1999 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical efficacy of interferon beta (IFN-beta) therapy in reducing exacerbations of relapsing-remitting MS has been related to antagonistic effects on various activities of IFN-gamma, including MHC-II gene induction.
|
9345390 |
1995 |